Ideaya Biosciences Q3 2026 Results: Net Loss of $126M
For the nine months ended September 30, 2026, IDEAYA Biosciences reported a net loss of $336.7 million, a significant increase from the $30.4 million loss in the prior year period, primarily due to a sharp decrease in collaboration revenue and increased R&D spending. The company strengthened its balance sheet through a follow-on public offering and warrant issuance, ending the period with approximately $1.15 billion in cash, cash equivalents, and marketable securities.
- Key figure
- Net loss $126M